Navigation Links
Schiffrin Barroway Topaz & Kessler, LLP Announces Court Ruling Relating to Merck & Co. Inc.'s Employee Savings & Security Plan, the Merck & Co., Inc. Employee Stock Purchase & Savings Plan, and the Merck Puerto Rico Employee Savings & Security Plan
Date:6/19/2008

RADNOR, Pa., June 19 /PRNewswire/ -- ADVERTISEMENT - The following statement was issued today by the law firm of Schiffrin Barroway Topaz & Kessler, LLP:

Schiffrin Barroway Topaz & Kessler, LLP is Co-Lead Counsel for the ERISA plaintiffs in the In re Merck & Co. Inc. Securities, Derivative, & ERISA Litigation, MDL No. 1658, pending in the U.S. District Court for the District of New Jersey. The Court recently ruled that claims for violations of the Employee Retirement Income Security Act of 1974 ("ERISA") relating to the failure of Merck & Co. Inc. ("Merck" or the "Company") (NYSE: MRK) to disclose material facts relating to Vytorin cannot be pursued as part of the ERISA action dealing with issues relating to Vioxx and should be pursued in a separate case. To date, lawsuits have been filed that allege that the investments in the Merck Common Stock Fund within the Merck & Co., Inc. Employee Savings & Security Plan, the Merck & Co., Inc. Employee Stock Purchase & Savings Plan, or the Merck Puerto Rico Employee Savings & Security Plan (collectively, the "Merck Plans") have declined substantially because Merck breached its fiduciary duties to participates of the Merck Plans when it failed to disclose material facts regarding Vytorin.

If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters and are or were a participant in the Merck & Co., Inc. Employee Savings & Security Plan, the Merck & Co., Inc. Employee Stock Purchase & Savings Plan, or the Merck Puerto Rico Employee Savings & Security Plan during the class period of April 1, 2006 through March 31, 2008, and were invested in the Merck Common Stock Fund, please contact Schiffrin Barroway Topaz & Kessler, LLP (Edward Ciolko, Esq. or Tiffany Melvin) toll free at 1-888-299-7706 or 1-610-667-7706, or via e-mail at info@sbtklaw.com.

Specifically, the new suits allege that Merck breached its fiduciary duties under ERISA by failing to disclose to participants of the Merck Plans that the results of the ENHANCE trial showed no statistically significant difference between patient use of Vytorin versus patients treated with Simvastatin. When the results of ENHANCE trial of Vytorin were made public on March 28, 2008 both the Merck Plans and the Merck Plans' participants and beneficiaries suffered significant losses as Merck's stock price and the value of the Merck Common Stock Fund in the Merck Plans drastically decreased. Additionally, the new suits allege that Merck breached its fiduciary duties to prudently and loyally invest and maintain the assets of the Merck Plans and provide adequate information to the participants of those Merck Plans through its actions and omissions, including but not limited to its conduct in relation to Vytorin.

Schiffrin Barroway Topaz & Kessler, LLP is one of America's leading law firms handling ERISA retirement plan litigation. We are committed to helping employees and retirees protect their retirement savings.

If you are a member of the class, you may retain Schiffrin Barroway Topaz & Kessler, LLP, you may retain other counsel, do nothing, or take other steps to protect your rights.

Before making your choice of attorney, you should give this matter careful thought. The selection of an attorney is an important decision. For more information about Schiffrin Barroway Topaz & Kessler please visit http://www.sbtklaw.com.

CONTACT: Schiffrin Barroway Topaz & Kessler, LLP

Edward Ciolko, Esquire

Tiffany Melvin

280 King of Prussia Road

Radnor, PA 19087

1-888-299-7706 (toll free) or 1-610-667-7706

Or by e-mail at info@sbtklaw.com


'/>"/>
SOURCE Schiffrin Barroway Topaz & Kessler, LLP
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Shareholder Class Action Filed Against WellPoint, Inc. by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
2. Shareholder Class Action Filed Against Candela Corporation by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
3. Shareholder Class Action Filed Against Humana Inc. by The Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
4. Shareholder Class Action Filed Against NeuroMetrix Inc. by The Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
5. Shareholder Class Action Filed Against American Dental Partners, Inc. by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
6. Shareholder Class Action Filed Against Health Management Associates, Inc. by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
7. Shareholder Class Action Filed Against Medtronic, Inc. by The Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
8. Shareholder Class Action Filed Against Aetna Inc. by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
9. NightHawk Radiology Holdings, Inc. Announces Final Results of Tender Offer; NightHawk Purchases 2,240,883 Shares of Its Common Stock at $8.05 per Share
10. Benda Pharmaceutical Announces Resignation of Board Member
11. Dilon Technologies Announces National Agreement with MedAssets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... It’s that time of year when ... president of the Interscholastic Athletic Association of Maryland (IAAM), Hall of Fame athlete and ... goals are cast aside. , That’s why one of her first decisions when her ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... businesses recover after a disaster, announced today the acquisition of Hawaii DKI. Hawaii ... , “Investing in like-minded companies who excel at service and response ...
(Date:2/9/2016)... MA (PRWEB) , ... February 09, 2016 , ... ... (WCRI) compares the workers’ compensation fee schedule rates and Medicare rates for a ... services covered in the report, Evaluation of the 2015 Fee Schedule Rates ...
(Date:2/9/2016)... ... February 09, 2016 , ... BioPlus Specialty Pharmacy (BioPlus), ... the ‘Pay It Forward’ program into 2016. BioPlus partners with several non-profit patient ... , “Since our Pay It Forward program began, we are proud to ...
(Date:2/9/2016)... ... 2016 , ... The Journal of Pain Research has published the ... , As corresponding author Dr John F. Peppin says “Terminology matters, yet little attention ... pain patients. ‘Chronic cancer pain’ and ‘chronic non-cancer pain’ are replete in the ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... BioSciences, Inc. (NASDAQ: SGMO ), the leader ... quarter and full year 2015 financial results and ... editing," said Edward Lanphier, Sangamo,s president and chief ... leads the therapeutic genome editing field and we ... our ground-breaking genome editing programs through IND enabling ...
(Date:2/9/2016)... QGEN ; Frankfurt Prime ... Genomics to develop and promote comprehensive solutions for ... --> QGEN ; Frankfurt Prime Standard: QIA) ... develop and promote comprehensive solutions for next-generation sequencing ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime ...
(Date:2/9/2016)... --  AllCare Plus Pharmacy announced today that it ... ® for Home Care Accreditation by ... Seal of Approval ® is a symbol of ... and effective care.  --> ... on-site survey in January 2016. The survey reflected compliance ...
Breaking Medicine Technology: